Blair William & Co. IL Sells 5,099 Shares of Abbott Laboratories $ABT

Blair William & Co. IL trimmed its holdings in Abbott Laboratories (NYSE:ABT) by 0.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 1,598,206 shares of the healthcare product maker’s stock after selling 5,099 shares during the quarter. Blair William & Co. IL owned approximately 0.09% of Abbott Laboratories worth $214,064,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of the business. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories in the third quarter worth about $29,000. Guerra Advisors Inc bought a new stake in shares of Abbott Laboratories during the third quarter valued at approximately $31,000. Anfield Capital Management LLC increased its holdings in Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after purchasing an additional 104 shares during the period. Delos Wealth Advisors LLC purchased a new stake in shares of Abbott Laboratories in the 2nd quarter worth $32,000. Finally, Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories in the third quarter valued at about $33,000. Institutional investors own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ABT. Raymond James Financial lowered their price target on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Leerink Partners dropped their target price on Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research report on Friday, January 30th. Evercore reduced their price target on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Freedom Capital upgraded Abbott Laboratories from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 29th. Finally, Barclays lowered their target price on shares of Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating for the company in a research note on Monday, February 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat, Abbott Laboratories currently has a consensus rating of “Moderate Buy” and a consensus price target of $137.05.

Insider Activity at Abbott Laboratories

In other Abbott Laboratories news, EVP Elizabeth C. Cushman sold 263 shares of Abbott Laboratories stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $30,397.54. Following the completion of the transaction, the executive vice president owned 38,573 shares of the company’s stock, valued at approximately $4,458,267.34. The trade was a 0.68% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 3,055 shares of company stock valued at $353,097 in the last quarter. 0.46% of the stock is currently owned by insiders.

Abbott Laboratories Trading Down 1.2%

NYSE ABT opened at $109.74 on Friday. The company has a fifty day moving average of $116.09 and a 200 day moving average of $124.67. The company has a market capitalization of $190.69 billion, a PE ratio of 29.50, a P/E/G ratio of 1.77 and a beta of 0.74. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $139.15.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. The business had revenue of $11.46 billion during the quarter, compared to analysts’ expectations of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.The company’s revenue for the quarter was up 4.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts forecast that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio is 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.